Latest Therapeutics in Alzheimer’s Disease: Systematic Review

• DOI: 10.61919/7x5c6d45
• Publication Date: 2025-05-16T08:25:30Z
• Authors: Muhammad Usman; Umar Bilal; Saman Rauf; Muhammad Saqib

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia globally, with no definitive disease-modifying treatment currently available. Recent therapeutic advances targeting amyloid-beta, tau protein, neuroinflammation, metabolic pathways reflect shift in paradigms. However, comparative efficacy, safety, translational potential these emerging strategies remain insufficiently synthesized. Objective: This systematic review aimed to evaluate latest interventions for AD by analyzing randomized clinical trials pilot studies assessing pharmacologic non-pharmacologic treatments, focus on cognitive outcomes, biomarker changes, safety. Methods: A was conducted following PRISMA 2020 guidelines. Databases searched included PubMed, Scopus, Web Science, Cochrane Library, covering publications from December 2018 August 2023. Studies were if they involving patients aged ≥18 years. Data interventions, risk bias extracted synthesized narratively. The final sample comprised 21 eligible trials. Ethical compliance Declaration Helsinki ensured all primary studies. Statistical outcomes effects reported descriptively. Results: Trials total over 7,000 participants. Lecanemab, Donanemab, BI 425809, masitinib demonstrated statistically significant improvements measures (e.g., ADCOMS, ADAS-Cog) modulation amyloid PET, levels). Intranasal insulin activators showed functional gains. Safety profiles generally favorable, though some had limited generalizability due size trial duration. Conclusion: Multiple show promise modifying trajectory Alzheimer’s disease, supporting move toward personalized mechanism-based approaches. These findings offer valuable insights highlight need integrated, large-scale translate into real-world patient care.